No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Internal radionuclide therapy: The ULMDOS software for treatment planning
1.P. B. Zanzonico, “Internal radionuclide radiation dosimetry: A review of basic concepts and recent developments,” J. Nucl. Med. 41, 297–308 (2000).
2.S. Shen, R.-F. Meredith, J. Duan, D.-J. Macey, M. B. Khazaeli, F. Robert, and A.-F. LoBuglio, “Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting -antibody therapy,” J. Nucl. Med. 43, 1245–1253 (2002).
3.G. Sgouros et al., “Patient-specific, 3-dimensional dosimetry in non-hodgkin’s lymphoma patients treated with -anti-B1 antibody: Assessment of tumor dose-response,” J. Nucl. Med. 44, 260–268 (2003).
4.K. Scheidhauer, I. Wolf, H. J. Baumgartl, C. Von-Schilling, B. Schmidt, G. Reidel, C. Peschel, and M. Schwaiger, “Biodistribution and kinetics of -labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin’s lymphoma,” Eur. J. Nucl. Med. Mol. Imaging 29, 1276–1282 (2002).
5.A. Helisch et al., “Pre-therapeutic dosimetry and biodistribution of -DOTA-Phe1-Tyr3-octreotide versus -pentetreotide in patients with advanced neuroendocrine tumours,” Eur. J. Nucl. Med. Mol. Imaging 31, 1386–1392 (2004).
6.R. M. Sharkey et al., “Radioimmunotherapy of non-hodgkin’s lymphoma with -DOTA humanized anti-CD22 IgG (-Epratuzumab): Do tumor targeting and dosimetry predict therapeutic response?,” J. Nucl. Med. 44, 2000–2018 (2003).
7.S. E. Strand, B. A. Jonsson, M. Ljungberg, and J. Tennvall, “Radioimmunotherapy dosimetry—a review,” Acta Oncol. 32, 807–817 (1993).
8.S. N. Reske et al., “Targeted bone marrow irradiation in the conditioning of high risk leukemia prior to stem cell transplantation,” Eur. J. Nucl. Med. 28, 807–815 (2001).
9.D. Bunjes et al., “Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: Results of a phase I-II study,” Blood 98, 565–572 (2001).
10.J. A. Siegel et al., “MIRD pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates,” J. Nucl. Med. 40, 37S–61S (1999).
11.J. Kotzerke et al., “Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: Differences in dosimetry and biokinetics of - and -labeled anti-NCA-95 MAbs,” J. Nucl. Med. 41, 531–537 (2000).
12.M. G. Stabin, “MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine,” J. Nucl. Med. 37, 538–546 (1996).
13.W. D. Erwin, M. W. Groch, D. J. Macey, G. L. DeNardo, S. J. DeNardo, and S. Shen, “A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy,” Nucl. Med. Biol. 23, 525–532 (1996).
14.K. S. Kolbert et al., “Implementation and evaluation of patient-specific three-dimensional internal dosimetry,” J. Nucl. Med. 38, 301–308 (1997).
15.A. Liu, L. E. Williams, G. Lopatin, D. M. Yamauchi, J. Y. Wong, and A. A. Raubitschek, “A radionuclide therapy treatment planning and dose estimation system,” J. Nucl. Med. 40, 1151–1153 (1999).
16.T. K. Johnson, D. McClure, and S. McCourt, “MABDOSE. I. Characterization of a general purpose dose estimation code,” Med. Phys. 26, 1389–1395 (1999).
17.K. Sjögreen, M. Ljungberg, and S. E. Strand, “An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to ,” J. Nucl. Med. 43, 972–982 (2002).
18.M. J. Guy, G. D. Flux, P. Papavasileiou, M. A. Flower, and R. J. Ott, “RMDP: A dedicated package for SPECT quantification, registration and patient-specific dosimetry,” Cancer Biother. Radiopharm. 18, 61–69 (2003).
19.E. McKay, “A software tool for specifying voxel models for dosimetry estimation,” Cancer Biother. Radiopharm. 18, 379–392 (2003).
20.I. Gardin, L. G. Bouchet, K. Assie, J. Caron, A. Lisbona, L. Ferrer, W. E. Bolch, and P. Vera, “Voxeldose: A computer program for 3-D dose calculation in therapeutic nuclear medicine,” Cancer Biother. Radiopharm. 18, 109–115 (2003).
21.G. Sgouros, K. S. Kolbert, A. Sheikh, K. S. Pentlow, E. F. Mun, A. Barth, R. J. Robbins, and S. M. Larson, “Patient-specific dosimetry for thyroid cancer therapy using PET and 3-dimensional-internal dosimetry (3D-ID) software,” J. Nucl. Med. 45, 1366–1372 (2004).
22.M. Neumann, “DICOM—current status and future developements for radiotherapy,” Z. Med. Phys. 12, 171–176 (2002).
23.G. Sgouros, M. Stabin, Y. Erdi, G. Akabani, C. Kwok, A. B. Brill, and B. Wessels, “Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components,” Med. Phys. 27, 2150–2164 (2000).
24.W. S. Snyder, M. J. Cook, E. S. Nasset, R. S. Karhausen, and G. P. Howells, Report of the Task Group on Reference Man. ICRP Publication 23 (Pergamon, New York, 1975).
25.R. J. Jaszczak, K. L. Greer, C. E. Floyd, Jr., C. C. Harris, and R. E. Coleman, “Improved SPECT quantification using compensation for scattered photons,” J. Nucl. Med. 25, 893–900 (1984).
26.C. W. Choi, W. C. Barker, I. Buvat, J. A. Carrasquillo, and S. L. Bacharach, “Implications of dual-energy-window (DEW) scatter correction inaccuracies for quantitative geometric mean imaging,” Nucl. Med. Commun. 18, 79–86 (1997).
27.T. Ichihara, K. Ogawa, N. Motomura, A. Kubo, and S. Hashimoto, “Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT,” J. Nucl. Med. 34, 2216–2221 (1993).
29.W. H. Press, S. A. Teukolsky, W. T. Vetterling, and B. P. Flannery (Cambridge University Press, New York, 1992), pp. 683–688.
30.J. A. Nelder and R. Mead, “A simplex method for function minimization,” Comput. J. 7, 308–313 (1965).
31.M. Stabin, “New internal radiation dose and modeling software; FDA approves commercial MIRDOSE successor,” J. Nucl. Med. 45, 26–27 (2004).
Article metrics loading...
Full text loading...
Most read this month